Sep 2026· International Journal of Molecular Sciences· Vol 27, pp. 8317· 0 citations· 227 references
Medicine
TL;DR
Current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia is examined and a practical framework for its assessment and management is provided to provide a practical framework for its assessment and management.
Abstract
Cardiovascular–kidney–metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced high-density lipoprotein-cholesterol (HDL-C), increased apolipoprotein B (apoB)-containing lipoproteins, remnant cholesterol (RC) accumulation, small dense low-density lipoprotein (LDL) particles, and frequently elevated lipoprotein(a) [Lp(a)]. Such lipid abnormalities contribute to accelerated atherosclerosis and early renal deterioration. In turn, kidney dysfunction further amplifies lipid abnormalities. These pathways underscore the need for a timely and comprehensive lipid assessment using apoB, non-HDL-C, RC, and Lp(a) within the CKM framework. Effective lipid management is crucial for CKM syndrome treatment, with the potential to reduce residual cardiovascular and renal risk and improve long-term clinical outcomes. In this narrative review, we examine current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia and provide a practical framework for its assessment and management. Management requires a multimodal approach tailored to the patient’s lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection.
Diabetic dyslipidemia is a complex metabolic abnormality characterized by hypertriglyceridemia, reduced high-density lipoprotein cholesterol (HDL-C), qualitative abnormalities of low-density lipoprotein (LDL) particles, and accumulation of triglyceride-rich lipoproteins (TRLs) and their remnants. Although LDL cholester...
HS Dr.Yogesh, Laksmi Prasannah, SK Kavitha· International Journal of Dru...· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome is an emerging clinical framework that integrates the interconnected burden of metabolic risk factors, chronic kidney disease, and cardiovascular disease. The syndrome is characterized by multidirectional pathophysiological interactions among dysfunctional adiposity, insul...
A. Varma· Journal of Association of Cl...· 1 citation
Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases s...
Ling-Ling Li, Yi-Xuan Feng, Xiao-Ya Li et al.· Frontiers in Cardiovascular...· 0 citations
Type 2 diabetes mellitus (T2DM) substantially increases the risk of acute coronary syndrome (ACS) through the combined effects of chronic hyperglycemia, dyslipidemia, oxidative stress, endothelial dysfunction, and myocardial injury. This study aimed to comprehensively evaluate metabolic, oxidative stress, and cardiac b...
S. H. Jwaid, H. Ahmed· Acta Medica Iranica· 0 citations
Type 2 diabetes mellitus (T2DM) is a key component of cardiovascular-kidney-metabolic (CKM) syndrome, an interconnected complex of metabolic disorders, chronic kidney disease (CKD), and cardiovascular disease (CVD). T2DM is characterized by chronic hyperglycemia resulting from insulin resistance and progressive impairm...
T. Demidova, M. Izmailova· National Health Care (Russia...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.